Jeffrey Aronin early in his career shadowed a physician, that chose to treat a child with medicine which spared the child from undergoing a complicated and invasive surgical procedure. The decision to treat the child with medicine improved the child’s condition and led Aronin on a path towards helping those afflicted by diseases or conditions that are considered rare or have little to no treatment options available.
Jeffrey Aronin and his team to keep pushing their dream of helping others live longer and better lives by conducting more research, bringing medications to market for the people suffering from conditions that have very little treatment options, if any available.
Aronin previously served as CEO of Ovation Pharmusuticals LLC. which was created in 2000 with the goal of helping patients with unmet medical needs, and especially ones with rare diseases. His main purpose was to create a company that was after one specific goal, catering to patients and their specific needs.
Jeffrey Aonin sold Ovation in 2009 for 900 million dollars to a Danish Company named Lundbeck. Jeffrey was kept on as CEO in hopes the company would continue with its success while going through the new transition of ownership. In the past 10 years, the Food and Drug Administration has approved 13 different medicines developed by Paragon’s portfolio companies. As current CEO and Chairman of Paragon Biosciences, Jeff has been a major factor in the company’s overall success.
The success of Jeffrey Aonin has attracted many investors, and companies looking for a strong partner to help them bring possible new medicines to market. Aronin is also very involved with the community, specifically those in Chicago directly related to healthcare. He currently sits as a board of directors for the World Business Chicago, which focuses on continued job growth. He was appointed a board member by the current Mayor Rahm Emanual. Jeffrey Aronin also sits as a board of director for Discover Financial Services.
Over the past 20 years, Jeffrey Aonin has helped create companies in the biotech and healthcare industry, where he has only strengthened his expertise in the areas of Drug development and rare diseases. Companies that dedicate themselves to helping patients specifically those diagnosed with rare conditions are sure to attract the interest of Jeff Aronin and the Paragon team.
read more about jeffery aronin below